Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ranibizumab - Novartis Ophthalmics

Next Previous
Drug Profile

Ranibizumab - Novartis Ophthalmics

Alternative Names: AMD Fab; Anti-VEGF fragment; Lucentis; Rabinismab; RG-3645; rhuFab V2; rhuFab V2 AMD; VEGF antibody fragment

Latest Information Update: 18 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genentech
  • Developer Genentech; Manhattan Eye, Ear & Throat Hospital; Novartis Ophthalmics; University of Bonn
  • Class Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Choroidal neovascularisation; Degenerative myopia; Diabetic macular oedema; Retinal oedema; Wet age-related macular degeneration
  • Registered Diabetic retinopathy
  • Phase III Retinopathy of prematurity
  • Phase I/II Polypoidal choroidal vasculopathy
  • Discontinued Retinal telangiectasis

Most Recent Events

  • 22 Sep 2018 Novartis announces intention to submit regulatory filings for marketing approval of Ranibizumab in Retinopathy of prematurity outside USA
  • 22 Sep 2018 Efficacy data from the phase III RAINBOW trial in Retinopathy of prematurity (In infants) released by Novartis
  • 21 Sep 2018 Roche initiates enrolment in a phase III trial of Port Delivery System (PDS) with ranibizumab for Neovascular age-related macular degeneration in the US (NCT03683251)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top